Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.

NCT01625182 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Interventions

DRUG: Fingolimod
DRUG: Placebo Comparator

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]